Bayer seeks Japanese approval for Eylea injections

[September 04, 2014]  FRANKFURT (Reuters) - Germany's Bayer said it has submitted an application for Japanese marketing authorization of Eylea to treat patients with a buildup of fluid in the back of the eye caused by a blockage of veins in the retina.

It said a late-stage drug trial showed that more patients with such a condition - macular edema secondary to branch retinal vein occlusion (BRVO) - showed an improvement in their ability to see when treated with Eylea compared with laser.

(Reporting by Maria Sheahan; Editing by Christoph Steitz)
 

[© 2014 Thomson Reuters. All rights reserved.]

Copyright 2014 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.